VERA | Vera Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	35.94 - 38.56
52 Week Range	9.24 - 50.78
Beta	1.01
Implied Volatility	59.37%
IV Rank	7.24%
Day's Volume	322,096
Average Volume	542,929
Shares Outstanding	54,827,700
Market Cap	2,039,590,440
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-05-14

Valuation
Profitability
Growth
Health
P/E Ratio	-16.99
Forward P/E Ratio	N/A
EPS	-2.19
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	55
Country	USA
Website	VERA

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

VERA's peers: THRD, CGEM, EWTX, RLYB, GLUE, TVTX, DICE, CYTK, VTYX, COGT, CNTB, TYRA, RAPT, XLO, MLYS, ANEB, ADAG, ACRV, ANAB, TARS, LIAN, ALDX, ETON

*Chart delayed

Analyzing fundamentals for VERA we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is passable. For more detailed analysis please see VERA Fundamentals page.

Watching at VERA technicals we can see that long-term trend is bullish, while middle-term trend is bearish, but short-term trend is bullish. More technicals details can be found on VERA Technicals page.